Hepatitis C vaccine is under clinical development by GeneCure Biotechnologies and currently in Phase I for Hepatitis C. According to GlobalData, Phase I drugs for Hepatitis C have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Hepatitis C vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hepatitis C vaccine overview
Vaccine is under development for the treatment of chronic hepatitis C infections. The vaccine candidate comprises of a gene (derived from hepatitis C virus) that is transferred into the host to produce gene products. The vaccine candidate is developed based on lentiviral-based gene transfer technology. It is administered through subcutaneous route.
GeneCure Biotechnologies overview
GeneCure Biotechnologies (GeneCure) is a privately-owned biotechnology company that specializes in the development of gene therapy-based technologies aimed at treating genetic and acquired human diseases. The company’s primary focus is on its patented gene transfer technology, which is being developed into treatments for various genetic diseases, infectious diseases, and cancers. Its lead product is HIVAX, a therapeutic HIV-1 vaccine for HIV-1 positive patients. The company’s platform technology is based on a primate lentivirus, which has been shown to efficiently deliver therapeutic genes. GeneCure’s products are primarily used in the healthcare industry, specifically in the treatment and prevention of diseases. The company’s business strategy involves entering corporate partnerships with established pharmaceutical companies interested in commercializing gene-based therapeutics. GeneCure is headquartered in Norcross, Georgia, the US
For a complete picture of Hepatitis C vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
